In December, MedPAC considered a package of draft recommendations related to the hospital inpatient and outpatient prospective payment systems. The package included a recommendation to reduce the payment rates for 340B hospitals’ Part B drugs by 10 percent of the average sales price and direct the program savings from reducing the payment rates to the Medicare-funded uncompensated care pool.
“This recommendation is outside of the scope of MedPAC’s mission, lacks a clear purpose and penalizes certain hospitals for their ability to obtain discounts on the items and services they purchase,” wrote Ashley Thompson, AHA senior vice president for public policy analysis and development, in a letter to MedPAC chairman Francis J. Crosson, MD.
The AHA urged MedPAC to withdraw the draft recommendation and, instead, to undertake an analysis of the trend of rapidly rising drug prices.
MedPAC is slated to vote next week on payment recommendations for fiscal year 2017.
More articles on healthcare finance:
55 hospitals sue HHS over changes to Medicare reimbursements
2 Texas hospitals file for bankruptcy: 5 things to know
Moody’s: 3 challenges facing the healthcare industry in 2016
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
